TY - JOUR
T1 - Characterization of metabolites and human P450 isoforms involved in the microsomal metabolism of mesaconitine
AU - Ye, Ling
AU - Tang, Lan
AU - Gong, Yun
AU - Lv, Chang
AU - Zheng, Zhijie
AU - JIANG, Zhi Hong
AU - Liu, Zhongqiu
N1 - Funding Information:
This work was mainly supported by the National Basic Research Program of China (973 Program, 2009CB5228008) and the Key Project of National Natural Science Foundation of China (U0832002). The authors would like to thank Alan ho of the School of Chinese Medicine of Hong Kong Baptist University for his technical assistance in the measurement of metabolites using LC-MS/MS.
PY - 2011/1
Y1 - 2011/1
N2 - Mesaconitine (MA), a major Aconitum alkaloid, provides effects against rheumatosis with high toxicity. To supply information for clinical safety, this study aims to investigate the metabolism of MA in male human liver microsomes (MHLMs) and the CYP isoforms involved in its metabolism. Metabolism studies were performed in vitro using MHLMs. Selective chemical inhibitors and recombinant human cytochrome P450 enzymes were used to confirm that the CYP isoforms contributed to MA metabolism. A total of nine metabolites were found and characterized in the MHLM incubations. The metabolic pathways were demethylation, dehydrogenation, hydroxylation, and demethylationdehydrogenation. Results showed that the inhibitor of CYP3A had a strong inhibitory effect; the inhibitors of CYP2C8, CYP2C9, CYP2C19, and CYP2D6 had modest inhibitory effects, whereas inhibitors of CYP1A2 and CYP2E1 had no obvious inhibitory effects on MA metabolism. Recombinant human cytochrome P450 isoforms CYP3A4 and CYP3A5 contributed greatly to the formation of MA metabolites, and CYP2C8, CYP2C9, and CYP2D6 played a minor role in the formation of MA metabolites. MA could be transformed into at least nine metabolites in MHLMs. MA might be metabolized by CYP3A4, CYP3A5, CYP2C8, CYP2C9, and CYP2D6 in MHLMs.
AB - Mesaconitine (MA), a major Aconitum alkaloid, provides effects against rheumatosis with high toxicity. To supply information for clinical safety, this study aims to investigate the metabolism of MA in male human liver microsomes (MHLMs) and the CYP isoforms involved in its metabolism. Metabolism studies were performed in vitro using MHLMs. Selective chemical inhibitors and recombinant human cytochrome P450 enzymes were used to confirm that the CYP isoforms contributed to MA metabolism. A total of nine metabolites were found and characterized in the MHLM incubations. The metabolic pathways were demethylation, dehydrogenation, hydroxylation, and demethylationdehydrogenation. Results showed that the inhibitor of CYP3A had a strong inhibitory effect; the inhibitors of CYP2C8, CYP2C9, CYP2C19, and CYP2D6 had modest inhibitory effects, whereas inhibitors of CYP1A2 and CYP2E1 had no obvious inhibitory effects on MA metabolism. Recombinant human cytochrome P450 isoforms CYP3A4 and CYP3A5 contributed greatly to the formation of MA metabolites, and CYP2C8, CYP2C9, and CYP2D6 played a minor role in the formation of MA metabolites. MA could be transformed into at least nine metabolites in MHLMs. MA might be metabolized by CYP3A4, CYP3A5, CYP2C8, CYP2C9, and CYP2D6 in MHLMs.
KW - Cytochrome P450
KW - LC-MS/MS
KW - Mesaconitine
KW - Metabolism
KW - Microsomes
UR - http://www.scopus.com/inward/record.url?scp=78650186681&partnerID=8YFLogxK
U2 - 10.3109/00498254.2010.524950
DO - 10.3109/00498254.2010.524950
M3 - Journal article
C2 - 21105783
AN - SCOPUS:78650186681
SN - 0049-8254
VL - 41
SP - 46
EP - 58
JO - Xenobiotica
JF - Xenobiotica
IS - 1
ER -